TABLE 2

Echocardiographic and NYHA Data

Patient no.	LVDd (mm)			LVDs (mm)			LVEF (%)
Patient no.		BSL	1 y	BSL	1 y	BSL	1 y	BSL	1 y
Carvedilol treatment group
1	66	48	56	38	31	42	3	1
2	55	51	46	40	32	42	3	2
3	56	58	45	44	40	56	3	2
4	73	59	65	45	23	47	3	2
5	64	54	48	40	47	51	3	2
6	67	67	62	56	12	33	3	2
7	50	46	42	32	33	58	3	1
8	55	53	43	36	44	60	3	2
9	62	56	55	46	25	36	3	2
10	75	52	67	38	22	53	3	2
11	76	67	67	53	23	42	3	2
12	64	56	55	40	28	54	3	1
13	67	55	58	42	30	47	3	2
14	62	44	48	28	45	66	2	1
15	67	59	56	48	34	38	3	2
Mean	64	55*	54	42*	31	48*	2.9	1.7*
±SD	±8	±7	±9	±7	±10	±10	±0.3	±0.5
Metoprolol treatment group
1	68	52	63	36	16	58	3	1
2	66	56	58	39	26	57	3	1
3	68	62	60	49	25	42	3	2
4	57	59	46	45	39	47	2	2
5	70	59	62	44	24	49	3	1
6	66	67	59	59	23	25	3	2
7	73	75	67	70	18	14	3	3
8	73	59	59	37	38	66	3	2
9	80	48	74	32	16	64	4	2
10	63	54	56	44	22	38	3	2
11	57	54	48	42	33	44	2	1
12	60	60	50	46	34	46	3	2
13	65	61	57	52	26	31	3	2
14	57	45	44	30	45	62	2	1
15	56	59	46	39	37	62	2	1
Mean	65	58*	57	44*	28	47*	2.8	1.7*
±SD	±7	±7	±8	±10	±9	±15	±0.6	±0.6

↵* P < 0.01 vs. BSL.
LVDd = left ventricular end-diastolic diameter; LVDs = left ventricular end-systolic diameter; BSL = baseline; 1 y = 1 y of study.